Antibody Search
OMIPs
eLearning 
Dye Directory
CD19 Vio Bright R720 (REA675, Human) - Reactivity: Human
Product Details
| Description | REA675 recognizes the human CD19 antigen, a type I transmembrane glycoprotein of 95 kDa that belongs to the immunglobulin superfamily. CD19 is expressed on B cells throughout most stages of B cell differentiation, though its expression is down-regulated during their terminal differentiation to plasma cells. Expression of CD19 is also found in the majority of B cell–derived malignancies. CD19 is further present on follicular dendritic cells. On B cells, CD19 associates with CD21, CD81, and CD225 (Leu-13) forming a signal transduction complex. | Additional information: Clone REA675 displays negligible binding to Fc receptors. | |
|---|---|---|
| Conjugate | Vio Bright R720 | |
| Clone | REA675 | |
| Target Species | Human | |
| Applications | FC, IHC, IF, Mass Cytometry, MICS (MACSima Imaging Cyclic Staining) | |
| Supplier | Miltenyi Biotec | |
| Catalog # | Sign in to view product details, citations, and spectra | |
| Size | ||
| Price | ||
| Antigen | ||
| Host | ||
| Isotype |
About CD19
This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
About Vio Bright R720
Vio® Bright R720 and Vio® R720 have an excitation peak at 695 nm and an emission peak at 720 nm, which means that these dyes are optimally excited by the 640 nm red laser while the emitted light is collected by the channel with a 725/40 bandpass filter. Miltenyi Biotec's proprietary multimerization technology allows for Vio® Bright R720 to be nearly twice the brightness of Vio® R720, so this choice of fluorophore offers flexibility in your panel design in flow cytometry. Spectrally, Vio® Bright R720 is comparable to R700 from BD Biosciences.
Vio® Bright R720 and Vio® R720 have an excitation peak at 695 nm and an emission peak at 720 nm, which means that these dyes are optimally excited by the 640 nm red laser while the emitted light is collected by the channel with a 725/40 bandpass filter. Miltenyi Biotec's proprietary multimerization technology allows for Vio® Bright R720 to be nearly twice the brightness of Vio® R720, so this choice of fluorophore offers flexibility in your panel design in flow cytometry. Spectrally, Vio® Bright R720 is comparable to R700 from BD Biosciences.
Experiment Design Tools
Spectra Viewer
Validation References
| Additional Sources |
|
|---|
Reviews & Ratings
| Reviews |
|---|
